Lead Product(s) : PF-04457845
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Jazz Pharmaceuticals
Deal Size : $410.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Acquires Spring Works Therapeutics' Faah Inhibitor Program
Details : Under the terms of the agreement, SpringWorks has assigned and exclusively licensed all assets relating to its FAAH inhibitor program to Jazz, including SpringWorks' proprietary FAAH inhibitor PF-04457845 and its license agreement with Pfizer, Inc.
Product Name : PF-04457845
Product Type : Other Small Molecule
Upfront Cash : $35.0 million
October 26, 2020
Lead Product(s) : PF-04457845
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Jazz Pharmaceuticals
Deal Size : $410.0 million
Deal Type : Acquisition